Table 2.
Clinical features of all included studies.
| Study | Pathology | Surgical resection | Diagnostic resection (%) | Recurrent disease (%) | Median target volume (cc) | Proton radiotherapy regimen | ||
|---|---|---|---|---|---|---|---|---|
| Total dose (GyRBE) | Fractions (n) | Dose/fraction (GyRBE) | ||||||
| Fuji, H. (2011) | Yes | NR | 100% | NR | 40 (7–546) (GTV) | 63 (50–70) | NR | 1.8 |
| Deraniyagala, R.L. (2014) | Yes | GTR 27%; STR 67%; Biopsy only 6% | 100% | 9% | NR | 74 (70–79) | NR | 1.8–2.0 |
| Grosshans, D.R. (2014) | Yes | GTR 20%; STR 80% | 100% | 6.70% | 15–26.2 | 69.8 (68–70) chordoma; 68.4 (66–70) chondrosarcoma | NR | 1.8–2.0 |
| Hayashi, Y. (2016) | Yes | GTR 42.1%; STR 47.3%; Biopsy only 10.6% | 100% | 36.80% | NR | 9 cases: 77.44; 10 cases: 78.4 | 77.44/64 bid; 78.4/56 bid | 1.2–1.4 |
| Weber, D.C. (2016) | Yes | GTR 3.2%; STR 96.8% | 100% | 23% | 35.7 ± 29.1 (GTV) | 72.5 ± 2.2 | NR | 1.8–2.0 |
| Hottinger, A.L. (2020) | Yes | GTR 13%; STR 83%; Biopsy4% | 100% | 24% | 26.3 (0.0–130.4) (GTV) | 74.0 (72.6–80.0) | NR | 1.8–2.5 |
| Gordon, K. (2021) | Yes | GTR 32.2%; STR 48.4% | 80.6% | 12.90% | 25.6 (4.2–115.6) (GTV) | 70 (60–74) | NR | 2 |